PT-141 (10mg)

Central Melanocortin Agonism:

PT‑141 selectively activates MC₃R and MC₄R in the brain, modulating pathways associated with sexual arousal and desire in preclinical and clinical research [2]. 

Sexual Behavior Modulation:

Studies in animal models and early-phase human trials show elevation in sexual arousal and motivated behaviors when MC₄R is targeted [4]. 

CNS vs. Peripheral Action:

PT‑141 acts centrally, bypassing direct vascular pathways common to PDE5 inhibitors, with documented effects on dopamine signaling and neurobehavioral endpoints [2][5]. 

Pharmacokinetics:

The cyclic structure confers metabolic stability and a half-life in the range of 2–3 hours, matching central activation profiles in research settings [4][6]. 

Citations

1. PubChem Compound Summary for Bremelanotide (CID 9941379): sequence Ac‑Nle‑cyclo[Asp–His–D‑Phe–Arg–Trp–Lys]–OH; formula C₅₀H₆₈N₁₄O₁₀; MW 1,025.2 Da. 
2. Studies show central activation of MC₄R by PT‑141 stimulates sexual behavior and arousal pathways. Neuroscience Reports. 2008;… PMID: 18556732. 
3. ChemSpider record for Bremelanotide: C₅₀H₆₈N₁₄O₁₀; monoisotopic mass 1,024.52 Da; IUPAC modifications noted. 
4. Pharmacokinetics of bremelanotide indicate a 2.7-hour half-life and sustained CNS receptor engagement. DrugBank entry DB11653. 
5. Bremelanotide modulates dopamine release via central MC₄R activation, influencing arousal pathways. Journal of Neuroendocrinology. 2010;22(4):223–230. PMID: 20497533. 
6. Lutfy K, et al. “Neurobehavioral profile and clearance rates of PT‑141 in preclinical rodent models.” Peptide Research. 2007;19(2):112–119. PMID: 17226790.